Resultados globales: 1 registros encontrados en 0.02 segundos.
Artículos, Encontrados 1 registros
Artículos Encontrados 1 registros  
1.
11 p, 1.1 MB Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs / Godman, Brian (University of Strathclyde) ; Malmström, Rickard E. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Diogène Fadini, Eduard (Hospital Universitari Vall d'Hebron) ; Jayathissa, Sisira (Hutt Valley DHB. Department of Medicine) ; McTaggart, Stuart (NHS National Services Scotland) ; Cars, Thomas (Uppsala University. Department of Medical Sciences) ; Alvarez-Madrazo, Samantha (University of Strathclyde) ; Baumgärtel, Christoph (Austrian Medicines and Medical Devices Agency) ; Brzezinska, Anna (Agency for Health Technology Assessment) ; Bucsics, Anna (Hauptverband der Österreichischen Sozialversicherungsträger) ; Campbell, Stephen (University of Manchester. Centre for Primary Care) ; Eriksson, Irene (Stockholm County Council. Department of Healthcare Development) ; Finlayson, Alexander (University of Oxford. Green Templeton College) ; Fürst, Jurij (Health Insurance Institute) ; Garuoliene, Kristina (National Health Insurance Fund) ; Gutiérrez-Ibarluzea, Iñaki (Osasun Saila. Ezagutu Osteba arloa) ; Hviding, Krystyna (Norwegian Medicines Agency) ; Herholz, Harald (Kassenärztliche Vereinigung Hessen) ; Joppi, Roberta (Azienda Sanitaria Locale of Verona. Pharmaceutical Drug Department) ; Kalaba, Marija (Republic Institute for Health. Department of Medicines and Pharmacoeconomics) ; Laius, Ott (State Agency of Medicines) ; Malinowska, Kamila (National Health Fund. Drug Management Department) ; Pedersen, Hanne B. (Division of Health Systems and Public Health, Health Technologies and Pharmaceuticals, WHO Regional Office for Europe) ; Markovic-Pekovic, Vanda (Ministry of Health and Social Welfare) ; Piessnegger, Jutta (Hauptverband der Österreichischen Sozialversicherungsträger) ; Selke, Gisbert (Wissenschaftliches Institut der AOK (WidO)) ; Sermet, Catherine (IRDES) ; Spillane, Susan (Trinity College. Department of Pharmacology and Therapeutics) ; Tomek, Dominik (Slovak Medical University. Faculty of Pharmacy) ; Vončina, Luka (Ministry of Health) ; Vlahović-Palčevski, Vera (University Hospital Rijeka. Unit for Clinical Pharmacology) ; Wale, Janet (Independent Consumer Advocate, VIC) ; Wladysiuk, Magdalena (HTA Consulting) ; van Woerkom, Menno (Dutch Institute for Rational Use of Medicine) ; Zara, Corinne (Institut Català de la Salut) ; Gustafsson, Lars L. (Karolinska University Hospital and Karolinska Institutet (Suècia)) ; Universitat Autònoma de Barcelona
Background : There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. [...]
2014 - 10.3389/fphar.2014.00109
Frontiers in Pharmacology, Vol. 5 (june 2014)  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.